Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134459 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Bifeprunox in Bipolar Depression
A Phase 3 study of Bipolar Disorder, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 434
- Enrollment target
- 20
- Study locations
NCT00134459 is a Phase 3 study of Bipolar Disorder that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 434 participants, above the 330-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT00134459, a Phase 3 study of Bipolar Disorder, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 434 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bifeprunox
Study Locations (20)
Florida
- - Bradenton
- - Jacksonville
- - Orlando
- - West Palm Beach
California
- - Beverly Hills
- - National City
- - Stanford
New Jersey
- - Clementon
- - Moorestown
Alabama
- - Birmingham
Connecticut
- - Farmington Hills
Georgia
- - Smyrna
Hawaii
- - Honolulu
Indiana
- - Terre Haute
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134459
The ClinicalTrials.gov registry entry for NCT00134459 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 434 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 330-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (32% higher). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00134459 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00134459 about?
NCT00134459 is a clinical study titled "Study Evaluating Bifeprunox in Bipolar Depression". The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
What is the current status of trial NCT00134459?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 434 participants. The study started on 2005-06. Estimated completion is 2006-05.
What conditions does trial NCT00134459 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT00134459?
The interventions under investigation include: Placebo (DRUG), Bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00134459?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134459 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RECRUITING · Phase 3
-
Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
COMPLETED · Phase 3
-
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
COMPLETED · Phase 3
-
Acute Treatment of Bipolar II Depression
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.